Artepharm Global Corp.

Artepharm is a pharmaceutical company specializing in the development and manufacturing of artemisinin-based combination therapies (ACTs) for the treatment of malaria. The company is best known for its flagship product, Artequick, which combines artemisinin and piperaquine to provide a rapid and effective treatment regimen. As a subsidiary of the Guangdong New South Group, Artepharm plays a pivotal role in international malaria elimination efforts, particularly through its Fast Elimination of Malaria by Source Eradication (FEMSE) strategy implemented in various African and Southeast Asian nations. The company maintains vertically integrated operations, encompassing the cultivation of medicinal plants, research and development, and large-scale GMP manufacturing. Artepharm's work is characterized by its close collaboration with academic institutions like the Guangzhou University of Chinese Medicine to advance antimalarial science and public health.